exact sciences, a darling of the CB market, made the somewhat predictable move of returning overnight on Monday with a new US$1bn eight-year convertible bond to replenish cash holdings. The new CB is already the medical diagnostic company's third, and largest deal in the past 20 months, leaving it with US$2.16bn of convertible debt that matures between 2025 and 2028.
展开▼
